Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Protalix Taliglucerase Alfa Receives French ATU Grant
Taliglucerase alfa is an enzyme replacement therapy that is expected to work by replacing the missing enzyme in Gaucher disease, helping to break down glucocerebroside and stopping it
Taliglucerase alfa is an enzyme replacement therapy that is expected to work by replacing the missing enzyme in Gaucher disease, helping to break down glucocerebroside and stopping it
Supernus expects to enroll 50 subjects in the study at 5 sites across the US. Supernus Pharma claimed that SPN812 is one of three compounds being developed by
Under the collaboration, both the entities will utilise IMD’s database of biologically active natural substances and Bioprofiling technology platform to discover functional ingredients for specific food applications, and
Mr Hockins has over 15 years of management experience in sales and marketing in the pharmaceutical, life sciences and in-vitro diagnostics sectors. He held various positions including director
David Howson, president of Accelr8, said: “We are very pleased to have a diagnostics innovator select OptiChem after comparing a number of competing coatings. Once again, OptiChem offered
Daiichi Sankyo has presented results of the study at the 21st International Congress on Thrombosis (ICT) in Milan, Italy. Daiichi Sankyo’s Phase III STARS E-3 study, in Japan
Additionally, BMS and Otsuka Pharma have received a priority review designation from the FDA for the sNDA. Sprycel, an oral BCR-ABL inhibitor, is currently approved by the FDA
As per the terms of the agreement, Genentech is expected to provide MRC Technology an upfront payment and also provide clinical development milestone payments and royalties on sales.
As per the terms of the agreement, OctoPlus is expected to perform process development and clinical manufacturing for The Medicines Company related to MDCO-216 (ApoA-I Milano/phospholipid complex). MDCO-216
Biogen Idec and Swedish Orphan Biovitrum said that the Phase 1/2a study of rFIXFc in 14 previously-treated patients with severe hemophilia B (less-than or equal to 2 U/dL